ClinicalTrials.gg
CompletedNCT00243386Updated May 19, 2021Results posted

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

A Phase 4 interventional study of Antihemophilic factor, recombinant, manufactured protein-free and Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 29 sites in 10 countries. Open to participants aged 7 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
7 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
3rd of 21
82 · median 50
Started
2006
with 1 other
Phase 4
8 of 21
1 open now
Registered
4th of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 4, and was the 4th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 7 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6 hours; actual dose determined by Baxter utilizing an algorithm and the patient's pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled patients will be treated originally on demand for a period of 6 months and then they will be randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of 12 months +/- 2 weeks.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
7 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level \<= 2% of normal, as tested at screening
  • The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant)
  • The subject is within 7 to 65 years of age
  • The subject has a performance score > (greater than) 60
  • The subject is negative (HIV-) or is HIV+ with a >= 400 cells/mm³ (CD4 count determined at screening, if necessary)
  • The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment
  • The subject has a documented history (e.g. in medical charts or dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment
  • The subject resides within the coverage area of the mobile compliance device; coverage area will be determined at screening
  • The subject or the subject's legally authorized representative has provided written

Exclusion criteria

Exclusion Criteria:

  • The subject has a known to factor VIII concentrates or mouse or hamster proteins
  • The subject has a history of factor VIII inhibitors with a titer >= 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening
  • The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (by Nijmegen Assay) in the central laboratory
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
  • The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative defect or von Willebrand's Disease)
  • The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug.
  • The subject has participated in another study within thirty (30) days of enrollment
  • The subject has previously participated in a clinical study with rAHF-PFM
  • The subject's clinical condition may require a major surgery (defined as moderate to critical risk and perioperative blood loss ≥ 500 mL) during the period of the subject's participation in the study
  • The subject is female of with a positive pregnancy test
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Active comparator
    1

    Standard prophylaxis

    Drug: Antihemophilic factor, recombinant, manufactured protein-free

  • Experimental
    2

    PK-driven prophylaxis

    Drug: Antihemophilic factor, recombinant, manufactured protein-free

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2): 1. Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator) 2. PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor) Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.

    Time frame: 12 months ±2 weeks

  2. Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.

    Time frame: 12 months ±2 weeks

Secondary outcomes

  1. Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR). Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

    Time frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)

  2. Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR) Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

    Time frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)

  3. Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens

    Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR). Any Prophylaxis = Standard or PK-Driven Prophylaxis Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

    Time frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)

  4. Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm

    Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.

    Time frame: 12 months ±2 weeks

  5. Bleeding Episodes Treated With 1 to ≥4 Infusions

    The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis

    Time frame: Throughout the study period (4 years and 5 months)

  6. Assessment of Hemostasis for Treatment of Bleeding Episodes

    Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale): Excellent: Full pain relief \& bleeding cessation within \~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis; Good: Definite pain relief and/or improvement in bleeding within \~8 hrs after infusion. Possibly requires \>1 infusion for complete resolution; Fair: Probable or slight relief of pain \& slight improvement in bleeding within \~8 hrs after infusion. Requires \>1 infusion for complete resolution; None: No improvement or condition worsens

    Time frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)

  7. Total Area Under the Curve (AUC)

    Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  8. Area Under the Curve

    Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  9. Maximum Plasma Concentration (C-max)

    Maximal Factor VIII Concentration After Infusion

    Time frame: Within 1 hour post-infusion

  10. Adjusted Incremental Recovery (IR)

    Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits. Adjusted IR defined as: \[Cmax (IU/dL) - pre-infusion FVIII (IU/dL)\]/dose (IU/kg)

    Time frame: 30 minutes pre-infusion to 48 hours post-infusion

  11. Terminal Half-life

    Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  12. Weight-Adjusted Clearance

    Computed as the weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  13. Mean Residence Time

    Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  14. Volume of Distribution at Steady State

    Computed as weight-adjusted clearance \* mean residence time

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  15. Factor VIII Inhibitor Development

    Number of treated participants who developed factor VIII inhibitors

    Time frame: Throughout study period (4 years and 5 months)

  16. Number of Participants With AEs Related to Investigational Product (IP)

    Number of treated participants with AEs judged to be possibly or probably related to treatment with IP

    Time frame: Throughout study period (4 years and 5 months)

  17. Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)

    Number of treated participants with 1 or more AE regardless of relatedness to IP

    Time frame: Throughout study period (4 years and 5 months)

  18. Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen

    Time frame: Throughout the study period (4 years and 5 months)

  19. Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen

    Time frame: Throughout the study period (4 years and 5 months)

  20. AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness

    Time frame: Throughout study period (4 years and 5 months)

  21. Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen

    This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs

    Time frame: Throughout the study period (4 years and 5 months)

  22. Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS

    Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

    Time frame: Baseline

  23. Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens

    Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

    Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)

  24. HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period

    Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

    Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)

  25. Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period

    Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.

    Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)

  26. Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period

    Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.

    Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)

07

Results

Posted Nov 20, 2012

Participant flow

Participants were enrolled at 21 European and 9 United States clinical sites beginning January 2006 and completing in June 2010

On-Demand Regimen (Study Part 1)
Participant flow — On-Demand Regimen (Study Part 1)
MilestoneAll Study ParticipantsPK-Driven ProphylaxisStandard Prophylaxis
Started7300
Completed6900
Not completed400
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up100
Withdrew: Screen failures200
End of Part 1, But Prior to Prophylaxis
Participant flow — End of Part 1, But Prior to Prophylaxis
MilestoneAll Study ParticipantsPK-Driven ProphylaxisStandard Prophylaxis
Started6900
Completed6600
Not completed300
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up100
Withdrew: Withdrawn for non-compliance100
PK-Driven or Standard Prophylaxis
Participant flow — PK-Driven or Standard Prophylaxis
MilestoneAll Study ParticipantsPK-Driven ProphylaxisStandard Prophylaxis
Started03432
Completed03132
Not completed030
Withdrew: Withdrawn for non-compliance020
Withdrew: Lack of efficacy010

Outcome measures

PrimaryMean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens

Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2): 1. Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator) 2. PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor) Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.

Time frame:
12 months ±2 weeks
Reported as:
Mean · (bleeds/year)^(1/2)
Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens
(bleeds/year)^(1/2)PK-Driven ProphylaxisStandard Prophylaxis
Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens1.61 ± 1.101.46 ± 0.98
Statistical analysis
  • PK-Driven Prophylaxis vs Standard Prophylaxis · t-test, 2 sided · p = 0.6016
SecondaryMean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens

Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR). Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

Time frame:
On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)
Reported as:
Mean · (bleeds/year)^(1/2)
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens
(bleeds/year)^(1/2)On-Demand Versus Standard Prophylaxis
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens5.29 ± 1.46
Statistical analysis
  • On-Demand Versus Standard Prophylaxis · Paired t-Test · p = <0.0001 (2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.)
SecondaryMean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens

Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR) Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

Time frame:
On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)
Reported as:
Mean · (bleeds/year)^(1/2)
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens
(bleeds/year)^(1/2)On-Demand Versus PK-Driven Prophylaxis
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens5.00 ± 1.85
Statistical analysis
  • On-Demand Versus PK-Driven Prophylaxis · Paired t-test · p = <0.0001 (2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.)
SecondaryMean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens

Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR). Any Prophylaxis = Standard or PK-Driven Prophylaxis Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).

Time frame:
On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)
Reported as:
Mean · (bleeds/year)^(1/2)
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens
(bleeds/year)^(1/2)On-Demand Versus Any Prophylaxis
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens5.14 ± 1.66
Statistical analysis
  • On-Demand Versus Any Prophylaxis · Paired t-test · p = <0.0001 (2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.)
SecondaryTotal Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm

Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.

Time frame:
12 months ±2 weeks
Reported as:
Median · IU/kg
Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm
IU/kgPK-Driven ProphylaxisStandard Prophylaxis
Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm5197.8 (3268.4 to 8273.5)5768.2 (4728.0 to 6425.4)
Statistical analysis
  • PK-Driven Prophylaxis vs Standard Prophylaxis · Wilcoxon-Rank Sum (Mann-Whitney) · p = 0.4924
SecondaryBleeding Episodes Treated With 1 to ≥4 Infusions

The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis

Time frame:
Throughout the study period (4 years and 5 months)
Reported as:
Number · Bleeding episodes
Bleeding Episodes Treated With 1 to ≥4 Infusions
Bleeding episodesOn-Demand TreatmentStandard Prophylaxis TreatmentPK-Driven Prophylaxis
1 infusion (n = 62, 13, 22)11686890
2 infusions (n = 51, 6, 9)2771237
3 infusions (n = 27, 2, 4)12845
4 or more infusions (n = 21, 5, 5)5097
SecondaryAssessment of Hemostasis for Treatment of Bleeding Episodes

Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale): Excellent: Full pain relief \& bleeding cessation within \~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis; Good: Definite pain relief and/or improvement in bleeding within \~8 hrs after infusion. Possibly requires \>1 infusion for complete resolution; Fair: Probable or slight relief of pain \& slight improvement in bleeding within \~8 hrs after infusion. Requires \>1 infusion for complete resolution; None: No improvement or condition worsens

Time frame:
On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)
Reported as:
Number · bleeding episodes
Assessment of Hemostasis for Treatment of Bleeding Episodes
bleeding episodesOn-Demand RegimenStandard ProphylaxisPK-Driven Prophylaxis
Excellent5473933
Good9433875
Fair1671611
None3020
Unknown1300
SecondaryTotal Area Under the Curve (AUC)

Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Geometric mean · IU*h/dL
Total Area Under the Curve (AUC)
IU*h/dL≥14 Years of Age<14 Years of Age
Total Area Under the Curve (AUC)1334.45 ± 454.331061.26 ± 452.87
SecondaryArea Under the Curve

Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Geometric mean · IU*h/dL
Area Under the Curve
IU*h/dL≥14 Years of Age<14 Years of Age
Area Under the Curve1213.98 ± 323.96966.68 ± 330.83
SecondaryMaximum Plasma Concentration (C-max)

Maximal Factor VIII Concentration After Infusion

Time frame:
Within 1 hour post-infusion
Reported as:
Geometric mean · IU/dL
Maximum Plasma Concentration (C-max)
IU/dL≥14 Years of Age<14 Years of Age
Maximum Plasma Concentration (C-max)91.12 ± 20.1574.47 ± 11.30
SecondaryAdjusted Incremental Recovery (IR)

Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits. Adjusted IR defined as: \[Cmax (IU/dL) - pre-infusion FVIII (IU/dL)\]/dose (IU/kg)

Time frame:
30 minutes pre-infusion to 48 hours post-infusion
Reported as:
Geometric mean · IU/dL per IU/kg
Adjusted Incremental Recovery (IR)
IU/dL per IU/kg≥14 Years of Age<14 Years of Age
Adjusted Incremental Recovery (IR)1.81 ± 0.411.47 ± 0.27
SecondaryTerminal Half-life

Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · hours
Terminal Half-life
hours≥14 Years of Age<14 Years of Age
Terminal Half-life13.91 ± 5.0714.66 ± 5.21
SecondaryWeight-Adjusted Clearance

Computed as the weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · mL/(kg*h)
Weight-Adjusted Clearance
mL/(kg*h)≥14 Years of Age<14 Years of Age
Weight-Adjusted Clearance3.89 ± 1.215.17 ± 1.94
SecondaryMean Residence Time

Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · hours
Mean Residence Time
hours≥14 Years of Age<14 Years of Age
Mean Residence Time17.71 ± 7.1617.88 ± 5.67
SecondaryVolume of Distribution at Steady State

Computed as weight-adjusted clearance \* mean residence time

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · dL/kg
Volume of Distribution at Steady State
dL/kg≥14 Years of Age<14 Years of Age
Volume of Distribution at Steady State0.65 ± 0.190.84 ± 0.19
SecondaryFactor VIII Inhibitor Development

Number of treated participants who developed factor VIII inhibitors

Time frame:
Throughout study period (4 years and 5 months)
Reported as:
Number · Participants
Factor VIII Inhibitor Development
ParticipantsAll Study Participants
Factor VIII Inhibitor Development0
SecondaryNumber of Participants With AEs Related to Investigational Product (IP)

Number of treated participants with AEs judged to be possibly or probably related to treatment with IP

Time frame:
Throughout study period (4 years and 5 months)
Reported as:
Number · Participants
Number of Participants With AEs Related to Investigational Product (IP)
ParticipantsAll Study Participants
Number of Participants With AEs Related to Investigational Product (IP)4
SecondaryNumber of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)

Number of treated participants with 1 or more AE regardless of relatedness to IP

Time frame:
Throughout study period (4 years and 5 months)
Reported as:
Number · Participants
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)
ParticipantsAll Study Participants
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)44
SecondaryNumber of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen
Time frame:
Throughout the study period (4 years and 5 months)
Reported as:
Number · participants
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen
participantsOn-DemandStandard ProphylaxisPK-Driven Prophylaxis
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen331519
SecondaryNumber of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen
Time frame:
Throughout the study period (4 years and 5 months)
Reported as:
Number · participants
Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen
participantsOn-DemandStandard ProphylaxisPK-Driven ProphylaxisSAEs Outside of the 3 Treatment Arms
ABDOMINAL PAIN1000
NAUSEA1000
TOOTH ABSCESS1000
JOINT DISLOCATION1000
HAEMOPHILIC ARTHROPATHY1010
SYNOVITIS1000
CALCULUS URINARY1000
HOSPITALIZATION1000
PULPITIS DENTAL0100
SOMNAMBULISM0100
FACTOR VIII INHIBITION (UNCONFIRMED)0010
APPENDICITIS0010
PAIN IN EXTREMITY0001
SecondaryAEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness
Time frame:
Throughout study period (4 years and 5 months)
Reported as:
Number · Events
AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness
EventsAll Study Participants
AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness39
SecondaryNumber of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen

This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs

Time frame:
Throughout the study period (4 years and 5 months)
Reported as:
Number · participants
Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen
participantsOn-DemandStandard ProphylaxisPK-Driven Prophylaxis
TOOTH ABSCESS (SAE)100
HAEMOPHILIC ARTHROPATHY (SAE)001
HAEMOPHILIC ARTHROPATHY (non-SAE)101
ABDOMINAL PAIN (non-SAE)100
ARTHRALGIA (non-SAE)100
SecondaryBaseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS

Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

Time frame:
Baseline
Reported as:
Median · Scores on a scale
Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS
Scores on a scaleAssessed Before Treatment
Physical Functioning (PF)44.56 (17.29 to 57.14)
Role-Physical (RP)42.10 (27.95 to 56.24)
Bodily Pain (BP)46.48 (25.07 to 62.75)
General Health (GH)43.87 (19.52 to 64.00)
Vitality (VT)51.42 (25.39 to 67.20)
Social Functioning (SF)46.28 (19.14 to 57.14)
Role-Emotional (RE)55.34 (23.74 to 55.34)
Mental Health (MH)50.44 (20.91 to 64.07)
Physical Component Score (PCS)42.32 (20.10 to 67.67)
Mental Component Score (MCS)52.65 (22.56 to 68.10)
SecondaryHealth-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens

Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

Time frame:
End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Reported as:
Median · Scores on a scale
Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens
Scores on a scaleOn-Demand TreatmentStandard ProphylaxisPK-Driven ProphylaxisAny Prophylaxis Treatment
Bodily Pain (BP)46.5 (29.4 to 62.8)51.6 (19.9 to 62.8)51.6 (29.4 to 62.8)51.6 (19.9 to 62.8)
General Health (GH)43.9 (19.5 to 64.0)48.6 (19.5 to 64.0)46.2 (29.8 to 60.3)48.6 (19.5 to 64.0)
Mental Component Score (MCS), On-Demand n=6254.9 (22.8 to 69.9)56.1 (13.3 to 69.6)54.5 (11.4 to 62.5)55.0 (11.4 to 69.6)
Mental Health (MH), On-Demand n=6251.6 (14.1 to 64.1)50.4 (20.9 to 64.1)52.7 (7.3 to 64.1)50.4 (7.3 to 64.1)
Physical Component Score (PCS), On-Demand n=6244.0 (16.1 to 61.2)50.2 (17.6 to 68.8)47.3 (25.3 to 62.3)47.8 (17.6 to 68.8)
Physical Functioning (PF), On-Demand n=6248.8 (17.3 to 57.1)46.7 (21.5 to 57.1)46.7 (17.3 to 57.1)46.7 (17.3 to 57.1)
Role Emotional (RE)55.3 (23.7 to 55.3)55.3 (23.7 to 55.3)55.3 (23.7 to 55.3)55.3 (23.7 to 55.3)
Role Physical (RP)49.2 (28.0 to 56.2)56.2 (28.0 to 56.2)56.2 (28.0 to 56.2)56.2 (28.0 to 56.2)
Social Functioning (SF)46.3 (30.0 to 57.1)51.7 (24.6 to 57.1)51.7 (13.7 to 57.1)51.7 (13.7 to 57.1)
Vitality (VT)53.8 (32.5 to 70.4)56.2 (27.8 to 70.4)56.2 (23.0 to 68.0)56.2 (23.0 to 70.4)
SecondaryHRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period

Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

Time frame:
End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Reported as:
Median · Scores on a scale
HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period
Scores on a scaleOn-Demand to Standard ProphylaxisOn-Demand to PK-Driven ProphylaxisOn-Demand to Any Prophylaxis Treatment
Physical Functioning (PF)0.00 (-10.48 to 14.68)-2.10 (-18.88 to 20.97)-2.10 (-18.88 to 20.97)
Role Physical (RP)0.00 (-28.29 to 21.21)0.00 (-28.29 to 28.29)0.00 (-28.29 to 28.29)
Bodily Pain (BP)0.00 (-29.55 to 17.55)-4.29 (-25.27 to 13.28)0.00 (-29.55 to 17.55)
General Health (GH)-3.74 (-29.55 to 17.55)-2.34 (-21.07 to 18.73)-2.34 (-20.13 to 17.79)
Vitality (VT)0.00 (-9.47 to 23.67)0.00 (-16.57 to 30.77)0.00 (-16.57 to 30.77)
Social Functioning (SF)0.00 (-21.72 to 16.29)0.00 (-16.29 to 16.29)0.00 (-21.72 to 16.29)
Role Emotional (RE)0.00 (-10.53 to 31.60)0.00 (-31.60 to 21.07)0.00 (-31.60 to 31.60)
Mental Health (MH)0.00 (-13.63 to 15.90)-1.13 (-40.90 to 34.08)0.00 (-40.90 to 34.08)
Physical Component Score (PCS)-2.55 (-20.22 to 8.69)-3.14 (-16.78 to 19.70)-2.76 (-20.22 to 19.70)
Mental Component Score (MCS)1.52 (-8.31 to 21.64)0.79 (-35.25 to 24.56)1.30 (-35.25 to 24.56)
PrimaryMedian Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens

Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.

Time frame:
12 months ±2 weeks
Reported as:
Median · Bleeds per year
Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens
Bleeds per yearPK-Driven ProphylaxisStandard Prophylaxis
Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens2.01 (0.00 to 17.06)1.00 (0.00 to 25.87)
Statistical analysis
  • PK-Driven Prophylaxis vs Standard Prophylaxis · Wilcoxon-Rank Sum (Mann-Whitney) · p = 0.1467
SecondaryBodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period

Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.

Time frame:
End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Reported as:
Median · Scores on a scale
Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period
Scores on a scale≥14 Years of Age
Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period0.00 (-29.55 to 17.55)
Statistical analysis
  • ≥14 Years of Age · Wilcoxon signed-rank test · p = 0.0007 (Due to multiple hypotheses testing results, adjusted alpha values are set to α\*=0.005 (0.05/10). Adjustments take into account 10 hypotheses tests between On-Demand and any Prophylaxis. Statistically significant results are considered p-values \< α\*)
SecondaryPhysical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period

Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.

Time frame:
End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Reported as:
Median · Scores on a scale
Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period
Scores on a scale≥14 Years of Age
Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period-2.76 (-20.22 to 19.70)
Statistical analysis
  • ≥14 Years of Age · Wilcoxon signed-rank test · p = 0.0002 (Due to multiple hypotheses testing results, adjusted alpha values are set to α\*=0.005 (0.05/10). Adjustments take into account 10 hypotheses tests between On-Demand and any Prophylaxis. Statistically significant results are considered p-values \< α\*)
Post-hocMedian (IQR) Annualized Bleed Rates

Bleed rates (number of bleeding episodes per subject) were annualized to account for the varying number of days a subject may have actually been on each regimen.

Time frame:
On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)
Reported as:
Median · Bleeding episodes
Median (IQR) Annualized Bleed Rates
Bleeding episodesOn-Demand RegimenStandard ProphylaxisPK-driven ProphylaxisAny Prophylaxis
Median (IQR) Annualized Bleed Rates43.98 (35.73 to 56.53)0.99 (0.00 to 2.14)1.00 (0.00 to 4.08)1.00 (0.00 to 4.07)
Statistical analysis
  • On-Demand Regimen vs Any Prophylaxis · Wilcoxon Signed-Rank Test · p = <0.0001

Adverse events

Collected over Throughout the study period (4 years and 5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-Demand—7/73 (9.6%)18/73 (24.7%)
Standard Prophylaxis—2/32 (6.3%)4/32 (12.5%)
PK-Driven Prophylaxis—3/34 (8.8%)7/34 (20.6%)
SAEs Outside of the 3 Treatment Arms—1/1 (100%)0/1 (0%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventOn-DemandStandard ProphylaxisPK-Driven ProphylaxisSAEs Outside of the 3 Treatment Arms
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders0/730/320/341/1
PULPITIS DENTALInfections and infestations0/731/320/340/1
SOMNAMBULISMPsychiatric disorders0/731/320/340/1
HAEMOPHILIC ARTHROPATHYMusculoskeletal and connective tissue disorders1/730/321/340/1
FACTOR VIII INHIBITIONBlood and lymphatic system disorders0/730/321/340/1
APPENDICITISInfections and infestations0/730/321/340/1
ABDOMINAL PAINGastrointestinal disorders1/730/320/340/1
NAUSEAGastrointestinal disorders1/730/320/340/1
TOOTH ABSCESSInfections and infestations1/730/320/340/1
JOINT DISLOCATIONInjury, poisoning and procedural complications1/730/320/340/1
Most frequent other events
Most frequent other events
EventOn-DemandStandard ProphylaxisPK-Driven ProphylaxisSAEs Outside of the 3 Treatment Arms
HEADACHENervous system disorders4/730/323/340/1
NASOPHARYNGITISInfections and infestations6/730/320/340/1
ARTHRALGIAMusculoskeletal and connective tissue disorders0/732/320/340/1
COUGHRespiratory, thoracic and mediastinal disorders0/732/320/340/1
IRRITABLE BOWEL SYNDROMEGastrointestinal disorders0/730/322/340/1
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/730/322/340/1
DIARRHOEAGastrointestinal disorders4/730/320/340/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants
Median26 (7 to 59)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female0
Male73
08

Study locations

29 sites
  • Los Angeles, California, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Minneapolis, Minnesota, United States
  • New York, New York, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Hershey, Pennsylvania, United States
  • Seattle, Washington, United States
  • Vienna, Austria
  • Brno, Czechia
  • Prague, Czechia
  • Athens, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pecs, Hungary
  • Szeged, Hungary
  • Szombathely, Hungary
  • Florence, Italy
  • Milano, Italy
  • Gdansk, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Warsaw, Poland
  • Wroclaw, Poland
  • Moscow, Russian Federation
  • Ljubljana, Slovenia
  • Cardiff, United Kingdom
  • Nottingham, United Kingdom
09

References and documents

Publications

  • Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x. PubMed 22212248 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Jun 2010, 53 months.

Results were first posted in Nov 2012, 2 years 5 months after primary completion. A results delay was requested in Jun 2011.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2005
First posted
Oct 24, 2005
StartActual
Jan 4, 2006
Primary completionActual
Jun 16, 2010
CompletionActual
Jun 16, 2010
Results delay requested
Jun 27, 2011
Results first posted
Nov 20, 2012
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00243386
Responsible party
Sponsor
First posted
Oct 24, 2005
Start date
Jan 4, 2006
Primary completion
Jun 16, 2010
Completion
Jun 16, 2010
Results posted
Nov 20, 2012
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion